Likewise, lymphocytes from CT26.CL25 tumor bearing mice also showed significantly less specific lysis against CT26.CL25 targets than did CTLs from CT26.CL25 PDT cured mice (P<0.05). This evidence concerns the gene DDX53 and neoplasm.